Aripiprazole in children with attention-deficit/hyperactivity disorder

Journal of Child and Adolescent Psychopharmacology

Volumn 18, Issue 4, 2008, Pages 347-354

  Findling, Robert L ^a   Short, Elizabeth J ^c   Leskovec, Thomas ^a   Townsend, Lisa D ^b   Demeter, Christine A ^a   McNamara, Nora K ^a   Stansbrey, Robert J ^a  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

^c CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE;

ARTICLE; ATTENTION DEFICIT DISORDER; CLINICAL ARTICLE; COGNITION; DRUG EFFECT; DRUG EFFICACY; DRUG WITHDRAWAL; EXTRAPYRAMIDAL SYMPTOM; FEMALE; FLU LIKE SYNDROME; HEADACHE; HICCUP; HUMAN; INCREASED APPETITE; MALE; MUSCULOSKELETAL PAIN; NAUSEA; OUTCOME ASSESSMENT; PARKINSONISM; PILOT STUDY; RATING SCALE; SCHOOL CHILD; SEDATION; SIDE EFFECT; SORE THROAT; STOMACH PAIN; TREATMENT RESPONSE; TREMOR; VOMITING; WEIGHT GAIN;

ANTIPSYCHOTIC AGENTS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CHILD; COGNITION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEADACHE; HUMANS; MALE; PILOT PROJECTS; PIPERAZINES; PSYCHIATRIC STATUS RATING SCALES; QUINOLONES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 50849103679     PISSN: 10445463     EISSN: None     Source Type: Journal    
DOI: 10.1089/cap.2007.0124     Document Type: Article

References (41)

1. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 4th ed. Washington DC: American Psychiatric Association, 1994.
2. Arnsten AF: Stimulants: Therapeutic actions in ADHD. Neuropsychopharmacology 31:2376-2383, 2006.
3. Barnes TRE: A rating scale for drug-induced akathisia. Br J Psychiatry 154:672-676, 1989.
4. Barzman DH, DelBello MP, Kowatch RA, Gernert B, Fleck DE, Pathak S, Rappaport K, Delgado SV, Campbell P, Strakowski SM: The effectiveness and tolerability of aripiprazole for pediatric bipolar disorders: A retrospective chart review. J Child Adolesc Psychopharmacol 14:593-600, 2004.
5. Biederman J, McDonnell MA, Wozniak J, Spencer T, Aleardi M, Falzone R, Mick Ě: Aripiprazole in the treatment of pediatric bipolar disorder: A systematic chart review. CNS Spectr 10:141-148, 2005.
6. Biederman J, Faraone SV: Attention-deficit hyperactivity disorder. Lancet 366:237-248, 2005.
7. Burris KD, Molski TF, Xu C, Ryan E, Tottori K, Kikuchi T, Yocca FD, Molinoff PB: Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther 302:381-389, 2002.
8. Chang KD, Nyilas M, Aurang C, Johnson B, Jin N, Marcus R, Forbes RA, Carson WH, Kahn A, Findling RL. Efficacy of aripiprazole in children (10-17 years old) with mania. Presented at: 54th Annual Meeting of the American Academy of Child and Adolescent Psychiatry. Boston, October 23-28, 2007.
9. Conners CK: Conners' Continuous Performance Tests, 2nd ed. Toronto (Canada), Multi-Health Systems, 1995.
10. Cutler AJ, Marcus RN, Hardy SA, O'Donnell A, Carson WH, McQuade RD: The efficacy and safety of lower doses of aripiprazole for the treatment of patients with acute exacerbation of schizophrenia. CNS Spectr 11:691-702, 2006.
11. Davies MA, Sheffler DJ, Roth BL: Aripiprazole: A novel atypical antipsychotic drug with a uniquely robust pharmacology. CNS Drug Rev 10:317-336, 2004.
12. Dunn LM, Dunn LM: PPVT-III-Peabody Picture Vocabulary Test, 3rd ed. Circle Pines (MN), American Guidance Service, 1997.
13. DuPaul GJ, Power TJ, Anastopoulos AD, Reid R: ADHD Rating Scale-IV. New York (NY), The Guilford Press, 1998.
14. Findling RL, Robb AS, Nyilas M, Forbes RA, McQuade RD, Mallikaarjun S, Pikalov A, Marcus R, Carson W. Tolerability of aripiprazole in the treatment of adolescents with schizophrenia. Presented at the American Psychiatric Association 160th Annual Meeting, San Diego, CA, May 19-24, 2007.
15. Findling RL, Blumer J, Kauffman R, Batterson J, Gilbert D, Bramer S, Marcus R, Carson W, Iwamoto T: Pharmacokinetic effects of aripiprazole in children and adolescents with conduct disorder. Int J Neuropsychopharmacol 7S1:S440, 2004 (abstract).
16. Golden CJ: Stroop Color and Word Test Children's Version for Ages 5-14. A Manual for Clinical and Experimental Uses. Wood Dale (IL), Stoelting, 2003.
17. Jordan S, Koprivica V, Chen R, Tottori K, Kikuchi T, Altar CA: The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor. Eur J Pharmacol 441:137-140, 2002.
18. Jordan S, Koprivica V, Dunn R, Tottori K, Kikuchi T, Altar CA: In vivo effects of aripiprazole on cortical and striatal dopaminergic and serotonergic function. Eur J Pharmacol 483:45-53, 2004.
19. Kane JM, Carson WH, Saha AR, McQuade RD, Ingenito GG, Zimbroff DL, Ali MW: Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry 63:763-771, 2002.
20. Kaufman J, Birmaher B, Brent D, Rao U, Flynn C, Moreci P, Williamson D, Ryan N: Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version (K-SADS-PL): Initial reliability and validity data. J Am Acad Child Psychiatry 36:980-988, 1997.
21. Keck PE Jr, Marcus R, Tourkodimitris S, Ali M, Liebeskind A, Saha A, Ingenito G; Aripiprazole Study: A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania. Am J Psychiatry 160:1651-1658, 2003.
22. Keck PE Jr, Calabrese JR, McQuade RD, Carson WH, Carlson BX, Rollin LM, Marcus RN, Sanchez R; Aripiprazole Study Group: A randomized, double-blind, placebo-controlled 26-week trial of aripiprazole in recently manic patients with bipolar I disorder. J Clin Psychiatry 67:626-637, 2006.
23. Kern RS, Green MF, Cornblatt BA, Owen JR, McQuade RD, Carson WH, Ali M, Marcus R: The neurocognitive effects of aripiprazole: An open-label comparison with olanzapine. Psychopharmacol (Berl) 187:312-320, 2006.
24. Kikuchi T, Tottori K, Uwahodo Y, Hirose T, Miwa T, Oshiro Y, Morita Š: 7-(4-[4-(2,3-Dichlorophenyl)-1-piperazinyl]butyloxy)-3,4-dihydro-2(1H) -quinolinone (OPC-14597), a new putative antipsychotic drug with both presynaptic dopamineautoreceptor agonistic activity and postsynaptic D2 receptor antagonistic activity. J Pharmacol Exp Ther 274:329-336, 1995.
25. Li Z, Ichikawa J, Dai J, Meltzer HY: Aripiprazole, a novel antipsychotic drug, preferentially increases dopamine release in the prefrontal cortex and hippocampus in rat brain. Eur J Pharmacol 493:75-83, 2004.
26. Molitch ME: Disorders of prolactin secretion. Endocrinol Metab Clin North Am 30:585-610, 2001.
27. Natesan S, Reckless GE, Nobrega JN, Fletcher PJ, Kapur S: Dissociation between in vivo occupancy and functional antagonism of dopamine D2 receptors: Comparing aripiprazole to other antipsychotics in animal models. Neuropsychopharmacology 31:1854-1863, 2006.
28. National Institute of Mental Health: Abnormal Involuntary Movement Scale (AIMS). Psychopharmacol Bull 21:1077-1080, 1985a.
29. National Institute of Mental Health: Clinical Global Impressions Scale. Psychopharmacol Bull 21:839-843, 1985b.
30. Pietrzak RH, Mollica CM, Maruff P, Snyder PJ: Cognitive effects of immediate-release methylphenidate in children with attention-deficit/ hyperactivity disorder. Neurosci Biobehav Rev 30:1225-1245, 2006.
31. Pigott TA, Carson WH, Saha AR, Torbeyns AF, Stock EG, Ingenito GG; Aripiprazole Study Group: Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: A placebo-controlled 26-week study. J Clin Psychiatry 64:1048-1056, 2003.
32. Pliszka SR: The neuropsychopharmacology of attention-deficit/ hyperactivity disorder. Biol Psychiatry 57:1385-1390, 2005.
33. Potkin SG, Saha AR, Kujawa MJ, Carson WH, Ali M, Stock E, Stringfellow J, Ingenito G, Marder SR: Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry 60:681-690, 2003.
34. Robb AS, Findling RL, Nyilas M, Forbes RA, McQuade RD, Mallikaarjun S, Pikalov A, Marcus R, Carson WH: Efficacy of aripiprazole in the treatment of adolescents with schizophrenia. Presented at the American Psychiatric Association 160th Annual Meeting, San Diego, CA, May 19-24, 2007
35. Sachs G, Sanchez R, Marcus R, Stock E, McQuade R, Carson W, Abou-Gharbia N, Impellizzeri C, Kaplita S, Rollin L, Iwamoto T; Aripiprazole Study Group: Aripiprazole in the treatment of acute manic or mixed episodes in patients with bipolar I disorder: A 3-week placebo-controlled study. J Psychopharmacol 20:536-546, 2006.
36. Semba J, Watanabe A, Kito S, Toru M: Behavioural and neurochemical effects of OPC-14597, a novel antipsychotic drug, on dopaminergic mechanisms in rat brain. Neuropharmacology 34:785-791, 1995.
37. Shaffer D, Gould MS, Brasic J, Ambrosini P, Fisher P, Bird H, Aluwahlia S: A Children's Global Assessment Scale (CGAS). Arch Gen Psychiatry 40:1228-1231, 1983.
38. Simpson GM, Angus JWS: A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 212:11-19, 1970.
39. Stigler KA, Posey DJ, McDougle CJ: Aripiprazole for maladaptive behavior in pervasive developmental disorders. J Child Adolesc Psychopharmacol 14:455-463, 2004.
40. Werry JS, Aman MG: Methylphenidate and haloperidol in children. Effects on attention, memory, and activity. Arch Gen Psychiatry 32:790-795, 1975.
41. Woodcock R, McGrew K, Mather N: Woodcock-Johnson III tests of achievement. Itasca (IL) Riverside Publishing, 2001.